[{"id":"b1ccf5af-a065-4ba7-b050-7e670664060b","acronym":"NEO-MIMAJOR","url":"https://clinicaltrials.gov/study/NCT05751928","created_at":"2023-03-02T15:01:35.752Z","updated_at":"2024-07-02T16:35:53.230Z","phase":"Phase 3","brief_title":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","source_id_and_acronym":"NCT05751928 - NEO-MIMAJOR","lead_sponsor":"Biocad","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Forteca (prolgolimab) • Nurdati (prolgolimab/nurulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2023-03-15"},{"id":"d48f7f6b-ee80-4a4b-bab1-707494af07db","acronym":"OCTAVA","url":"https://clinicaltrials.gov/study/NCT05732805","created_at":"2023-02-17T15:00:50.537Z","updated_at":"2024-07-02T16:35:55.249Z","phase":"Phase 3","brief_title":"A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma","source_id_and_acronym":"NCT05732805 - OCTAVA","lead_sponsor":"Biocad","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Forteca (prolgolimab) • Nurdati (prolgolimab/nurulimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-02-17"},{"id":"be589c90-92e3-4a29-b9c9-dfc3c78e4b13","acronym":"OBERTON","url":"https://clinicaltrials.gov/study/NCT03913923","created_at":"2021-01-18T19:15:39.098Z","updated_at":"2024-07-02T16:35:55.831Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT03913923 - OBERTON","lead_sponsor":"Biocad","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Forteca (prolgolimab) • Nurdati (prolgolimab/nurulimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-02-10"}]